Abstract
Background
High blood pressure (BP) is the single largest contributor to mortality world-wide.
Aim
To investigate the effectiveness of a pharmacists-led intervention to improve BP control using automated office blood pressure (AOBP).
Method
In this prospective parallel group, unblinded, cluster-randomised trial, 54 pharmacies enrolled pre-treated patients with uncontrolled AOBP above 135/85 mmHg. In the interventional group, pharmacists referred patients to the treating physician for therapy intensification in a structured fashion. In the control group, AOBP was recorded until the end of the trial. The primary endpoint was the proportion of patients achieving BP control at the threshold of 135/85 mmHg after 10 weeks. Key secondary endpoints were systolic AOBP reductions after 10 and 20 weeks.
Results
A total of 497 patients were included between 2017 and 2019. In the interventional and control group, 61.5% and 19.8% of patients underwent a therapy modification within 20 weeks. The primary endpoint was achieved in 38.8% in the interventional group and 31.2% in the control group (mean difference 7.6%, 95% CI −8.1; 23.3, p = 0.336). Mean systolic AOBP reductions were greater in the interventional vs. control group at 10 and 20 weeks (14.3 ± 7.4 vs. 6.9 ± 7.0 mmHg, mean difference 7.3 mmHg, 95% CI 3.2;11.5, p < 0.001, and 15.5 ± 9.0 vs. 9.8 ± 7.5 mmHg, mean difference 5.8 mmHg, 95% CI 0.8;10.7, p = 0.023). Atrial fibrillation was newly detected in 7.8% of patients.
Conclusion
Through a pragmatic pharmacist-led disease management program, BP control was improved over time, without significant differences between groups. Greater systolic AOBP reductions were observed in the interventional vs. control group. (Pharmacists Intervention to Improve Hypertension Management in Primary Care:APOTHECARE; ClinicalTrials.gov registration NCT03274531).
Similar content being viewed by others
References
Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959–68.
Banegas JR, Lopez-Garcia E, Dallongeville J, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011;32:2143–52.
Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–60.
Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114–7.
Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399–407.
Rohla M, Haberfeld H, Tscharre M, et al. Awareness, treatment, and control of hypertension in Austria: a multicentre cross-sectional study. J Hypertens. 2016;34:1432–40.
Milman T, Joundi RA, Alotaibi NM, et al. Clinical inertia in the pharmacological management of hypertension: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e11121.
Perl S, Niederl E, Kos C, et al. Randomized evaluation of the effectiveness of a structured educational program for patients with essential hypertension. Am J Hypertens. 2015:9:866-72.
Perl S, Riegelnik V, Mrak P, et al. Effects of a multifaceted educational program on blood pressure and cardiovascular risk in hypertensive patients: the Austrian Herzleben project. J Hypertens. 2011;29:2024–30.
Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev. 2004: CD004804.
Victor RG, Lynch K, Li N, et al. A cluster-randomized trial of blood-pressure reduction in black barbershops. N Engl J Med. 2018;378:1291–301.
Santschi V, Chiolero A, Colosimo AL, et al. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014;3:e000718.
Rohla M, Haberfeld H, Sinzinger H, et al. Systematic screening for cardiovascular risk at pharmacies. Open Heart. 2016;3:e000497.
Chambers LW, Kaczorowski J, O’Rielly S, et al. Comparison of blood pressure measurements using an automated blood pressure device in community pharmacies and family physicians’ offices: a randomized controlled trial. CMAJ Open. 2013;1:E37–42.
Myers MG, Godwin M. Automated office blood pressure. Can J Cardiol. 2012;28:341–6.
Myers MG, Godwin M, Dawes M, et al. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ. 2011;342:d286.
Myers MG, Valdivieso M, Kiss A. Use of automated office blood pressure measurement to reduce the white coat response. J Hypertens. 2009;27:280–6.
Roerecke M, Kaczorowski J, Myers MG. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. JAMA Intern Med. 2019;179:351–62.
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.
Chan PH, Wong CK, Pun L, et al. Diagnostic performance of an automatic blood pressure measurement device, Microlife WatchBP Home A, for atrial fibrillation screening in a real-world primary care setting. BMJ Open. 2017;7:e013685.
Wiesel J, Fitzig L, Herschman Y, et al. Detection of atrial fibrillation using a modified microlife blood pressure monitor. Am J Hypertens. 2009;22:848–52.
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104.
Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009;53:646–53.
Donner A, Klar N. Statistical considerations in the design and analysis of community intervention trials. J Clin Epidemiol. 1996;49:435–9.
Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.
Myers MG, Godwin M, Dawes M, et al. The conventional versus automated measurement of blood pressure in the office (CAMBO) trial: masked hypertension sub-study. J Hypertens. 2012;30:1937–41.
Wright JT Jr, Williamson JD, Whelton PK, et al. A Randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16.
Tsuyuki RT, Al Hamarneh YN, Jones CA, et al. The effectiveness of pharmacist interventions on cardiovascular risk: the multicenter randomized controlled RxEACH trial. J Am Coll Cardiol. 2016;67:2846–54.
Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention program to enhance hypertension control: a randomised controlled trial. Int J Clin Pharm. 2011;33:132–40.
Rohla M, Weiss TW, Pecen L, et al. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open. 2019;9(3):e022478. https://doi.org/10.1136/bmjopen-2018-022478
Acknowledgements
We would like to acknowledge the Pharmacists College of Austria (Apothekerkammer Zentrale), Mag. Elisabeth Biermeier of the Pharmacists College of Lower Austria, Assoc. Prof. DDr. Philipp Saiko of the Pharmacists College of Vienna, the Health Insurance Fund of Lower Austria (NÖGUS) as well as all participating pharmacists in Lower Austria and Vienna, who willingly supported our research.
Funding
The work was supported by the Pharmacists College of Lower Austria (Apothekerkammer Niederösterreich) and the Health Insurance Fund of Lower Austria (NÖGUS).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
MR received speaker and advisory fees from Daiichi Sankyo, Sanofi Aventis and COR2ED outside the submitted work. HH and MT report no conflicts of interest. KH received lecturing fees and advisory honoraria from Boehringer Ingelheim, Pfizer/BMS, Bayer, Daiichi Sankyo, Sanofi-Aventis, AstraZeneca, and Eli Lilly outside the submitted work. TWW received lecturing fees and advisory honoraria from Daiichi Sankyo, Boehringer Ingelheim and Pfizer/BMS outside the submitted work.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Rohla, M., Haberfeld, H., Tscharre, M. et al. Pharmacist interventions to improve blood pressure control in primary care: a cluster randomised trial. Int J Clin Pharm 45, 126–136 (2023). https://doi.org/10.1007/s11096-022-01452-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-022-01452-1